School of Computing Science, Newcastle University, 1 Science Square, Newcastle, NE4 5TG, UK.
Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, Netherlands.
Sci Rep. 2020 May 21;10(1):8427. doi: 10.1038/s41598-020-64643-8.
Conventional inclusion criteria used in osteoarthritis clinical trials are not very effective in selecting patients who would benefit from a therapy being tested. Typically majority of selected patients show no or limited disease progression during a trial period. As a consequence, the effect of the tested treatment cannot be observed, and the efforts and resources invested in running the trial are not rewarded. This could be avoided, if selection criteria were more predictive of the future disease progression. In this article, we formulated the patient selection problem as a multi-class classification task, with classes based on clinically relevant measures of progression (over a time scale typical for clinical trials). Using data from two long-term knee osteoarthritis studies OAI and CHECK, we tested multiple algorithms and learning process configurations (including multi-classifier approaches, cost-sensitive learning, and feature selection), to identify the best performing machine learning models. We examined the behaviour of the best models, with respect to prediction errors and the impact of used features, to confirm their clinical relevance. We found that the model-based selection outperforms the conventional inclusion criteria, reducing by 20-25% the number of patients who show no progression. This result might lead to more efficient clinical trials.
在骨关节炎临床试验中使用的传统纳入标准在选择可能从正在测试的治疗中受益的患者方面效果并不理想。通常情况下,大多数入选的患者在试验期间没有或仅有有限的疾病进展。因此,无法观察到测试治疗的效果,并且投入运行试验的努力和资源也没有得到回报。如果选择标准更能预测未来的疾病进展,就可以避免这种情况。在本文中,我们将患者选择问题表述为一个多类分类任务,其类别基于与进展相关的临床指标(在临床试验的典型时间尺度上)。我们使用来自两个长期膝关节骨关节炎研究 OAI 和 CHECK 的数据,测试了多种算法和学习过程配置(包括多分类器方法、代价敏感学习和特征选择),以确定性能最佳的机器学习模型。我们检查了最佳模型的行为,包括预测误差和使用特征的影响,以确认其临床相关性。我们发现基于模型的选择优于传统的纳入标准,可以将没有进展的患者数量减少 20-25%。这一结果可能会导致更有效的临床试验。